Abstract 373P
Background
Head and neck squamous cell carcinoma (HNSCC) is a common cancer worldwide with high mortality rates. Studies suggested the incidence of HNSCC will increase by approximately 30% by 2030. However, elderly patients with advanced HNSCC often face challenges in receiving sufficient treatment because of their lower tolerance to therapy. Exploring different approaches for HNSCC is crucial given the world's aging population.
Methods
The study between 2010 and 2021 involved patients with HNSCC located in the oral cavity, oropharynx, larynx, and hypopharynx. The research was focused on advanced-stage patients aged 70 or older. The data were collected from a cancer registry database at a referral institution. The Kaplan-Meier method was used to estimate overall survival (OS).
Results
The study included 1144 patients with HNSCC, of whom 207 (18.1%) were above 70 years old. Over 50% of the patients had advanced disease without metastasis, being stages III, IVA and IVB. The median OS for geriatric patients with advanced disease was 16.1 months. Patients who underwent curative-intent surgery, radiotherapy, or chemoradiotherapy had better survival rates than those who did not (log-rank test: all p < .01). Furthermore, patients with a higher body mass index (≥ 18.5) had improved OS (p = .03). No significant differences were observed in OS between geriatric patients who received systemic therapy or not. By the multivariate analysis, patients who underwent surgery demonstrated higher survival rates, while those with tumors located in the hypopharynx showed inferior outcomes. The median OS was 29.9 and 8.4 months, respectively (p < .01 and p = .01). Table: 373P
AJCC stage III and IV (M0) head and neck cancer (p < .01)
≥ 70-year-old patients | Number | 3-year survival rate |
Withoout curative surgery | 62 | 22.6% |
With curative surgery | 44 | 45.5% |
Conclusions
Geriatric patients with locally advanced HNSCC have a poor prognosis especially for hypopharyngeal cancer. The study suggests that curative surgery may be a beneficial treatment for these patients. However, further research is warranted to optimize treatments and improve outcomes and quality of life for this vulnerable group.
Clinical trial identification
Editorial acknowledgement
The authors would like to thank all colleagues who contributed to this study. The work was supported by the medical integration database of National Taiwan University Hospital and National Taiwan University Hospital Yunlin branch.
Legal entity responsible for the study
Y.T. Liu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract